GlassScriptPhysician profile
Joaquin Reyes
NPI 1295720316
$2,969.85
in general payments reported to CMS, 2019-2025
23 companies · $535 in 2025
The $535 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $284 · 2021: $276 · 2022: $489 · 2023: $413 · 2024: $543 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $536.74 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $361.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $348.63 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $338.65 | 2021-2025 | |
| Merz North America, INC. | $206.70 | 2022 | |
| Amgen INC. | $201.85 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $172.68 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $144.01 | 2019-2023 | Belsomra, Steglatro |
| Exact Sciences Corporation | $98.47 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $88.83 | 2023-2025 | Gvoke Hypopen |
| Allergan, INC. | $71.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.58 | 2023-2024 | Jardiance |
| Galderma Laboratories, L.P. | $45.58 | 2021 | |
| Pfizer INC. | $44.75 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.49 | 2023 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $40.37 | 2023 | |
| Corcept Therapeutics | $37.63 | 2025 | Korlym |
| Ardelyx, INC. | $32.35 | 2025 | Ibsrela |
| Abbvie INC. | $30.19 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.33 | 2019 | |
| Edwards Lifesciences Corporation | $18.24 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $16.01 | 2025 | Breztri |
| Dexcom, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joaquin Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.